us patent granted, page-33

It's the same definition MG... Several = "more than two or three but fewer than many"

My reply was simply answering your previous question: "Have they identified 3 opportunities and 2 partners or 30 opportunities...?"

They have most likely had many more "opportunities" along the way but as stated they have now "identified several commercial opportunities"

30 opportunities? Maybe! 30 commercial opportunities for the Dermaportation technology? No. As stated they have now identified "Several commercial" opportunities.

The first material announcement to highlight a commercial licensing agreement for the Dermaportation technology will send the sp into orbit, so having at least 4 on the table right now is quite exciting news imo... The market always requires a little more time to absorb this kind of information and I think its more than evident now that they don't understand the companys strategy, nor does the market appear to understand OBJ's 3 technology platforms...

A term frequently used by OBJ which should be taken more notice of imo is "targeted partners"...

OBJ from day one have advised the market that they choose the partners they wish to collaborate with and they choose those partners who shall fully fund their projects...

There is not one other company listed on the ASX that the the power over their technology the board of OBJ have to do this.

"OBJ’s primary strategy of engaging targeted potential licensees for the technology has and remains a principal route to commercialisation..."

OBJ isn't developing "me-too" products like the majority of listed biotech and medical device companies in our market do. It takes time to develop "NEW" products and new products which will help provide a new paradigm shift in healthcare.

"Over the period, the Company has undertaken significant expansion to its IP and Patent portfolios with the lodgement of 6 additional "Field of Use" patent applications covering the major commercial areas of interest to OBJ's partner companies and the progression of its foundation patents through to final examination in both the USA and Europe. These programs are designed to provide OBJ with broad exclusivity across key markets and to allow efficient and effective licensing across key market sectors."